Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.

Berenice Y Gitomer

TitleProfessor-Research
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-1685

    Collapse Research 
    Collapse research activities and funding
    R01DK128842     (CHONCHOL, MICHEL BENJAMIN)Sep 22, 2021 - Jun 30, 2026
    NIH
    Kidney Stone Disease In ADPKD
    Role: Co-Principal Investigator
    R21DK129720     (BJORNSTAD, PETTER M)Aug 1, 2021 - Jul 31, 2022
    NIH
    Measuring metabolically active kidney tissue in autosomal dominant polycystic kidney disease
    Role: Co-Principal Investigator
    R01DK114424     (KLAWITTER, JELENA)Sep 15, 2018 - Jun 30, 2021
    NIH
    The role of inflammation in the progression of polycystic kidney disease
    Role: Co-Principal Investigator
    R01DK097081     (CHONCHOL, MICHEL BENJAMIN)Jun 7, 2013 - Mar 31, 2017
    NIH
    Mineralocorticoid Antagonism and Endothelial Dysfunction
    Role: Co-Principal Investigator
    R01DK094796     (CHONCHOL, MICHEL BENJAMIN)Sep 30, 2012 - Jul 31, 2018
    NIH
    FGF-23 and clinical outcomes in ADPKD patients
    Role: Co-Principal Investigator
    R01DK090005     (GITOMER, BERENICE YOLANDE)Sep 20, 2011 - Aug 31, 2016
    NIH
    Dysregulated Angiogenesis in ADPKD
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Gitomer BY, Wang W, George D, Coleman E, Nowak KL, Struemph T, Cadnapaphornchai MA, Patel NU, Jovanovich A, Klawitter J, Farmer B, Ostrow A, You Z, Chonchol M. Statin therapy in patients with early-stage autosomal dominant polycystic kidney disease: Design and baseline characteristics. Contemp Clin Trials. 2024 02; 137:107423. PMID: 38151173.
      View in: PubMed
    2. Yang X, Wang W, Gitomer B, Cadnapaphornchai MA, Xing F, Chonchol M. Imaging Biomarkers in Young Patients With ADPKD. Kidney Int Rep. 2023 Oct; 8(10):2153-2155. PMID: 37850021.
      View in: PubMed
    3. Kleczko EK, Nguyen DT, Marsh KH, Bauer CD, Li AS, Monaghan MT, Berger MD, Furgeson SB, Gitomer BY, Chonchol MB, Clambey ET, Zimmerman KA, Nemenoff RA, Hopp K. Immune checkpoint activity regulates polycystic kidney disease progression. JCI Insight. 2023 06 22; 8(12). PMID: 37345660.
      View in: PubMed
    4. Steele CN, Oh ES, Wang W, Farmer-Bailey H, Gitomer BY, Chonchol M, Nowak KL. Cerebrovascular Pulsatility Index Is Reduced in Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol. 2023; 54(5-6):165-174. PMID: 37231790.
      View in: PubMed
    5. Perrone RD, Oberdhan D, Ouyang J, Bichet DG, Budde K, Chapman AB, Gitomer BY, Horie S, Ong ACM, Torres VE, Turner AN, Krasa H. OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD. Kidney Int Rep. 2023 May; 8(5):989-1001. PMID: 37180499.
      View in: PubMed
    6. Nguyen DT, Kleczko EK, Dwivedi N, Monaghan MT, Gitomer BY, Chonchol MB, Clambey ET, Nemenoff RA, Klawitter J, Hopp K. The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression. JCI Insight. 2023 01 10; 8(1). PMID: 36422996.
      View in: PubMed
    7. Klawitter J, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Christians U, Klawitter J. Kynurenines in polycystic kidney disease. J Nephrol. 2023 01; 36(1):83-91. PMID: 35867237.
      View in: PubMed
    8. Hoover E, Perrone RD, Rusconi C, Benson B, Dahl NK, Gitomer B, Manelli A, Mrug M, Park M, Seliger SL, Phadnis MA, Thewarapperuma N, Watnick TJ. Design and Basic Characteristics of a National Patient-Powered Registry in ADPKD. Kidney360. 2022 08 25; 3(8):1350-1358. PMID: 36176661.
      View in: PubMed
    9. Klawitter J, Sempio C, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Christians U, Klawitter J. Endocannabinoid System in Polycystic Kidney Disease. Am J Nephrol. 2022; 53(4):264-272. PMID: 35263737.
      View in: PubMed
    10. Hopp K, Kleczko EK, Gitomer BY, Chonchol M, Klawitter J, Christians U, Klawitter J. Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease. Am J Physiol Renal Physiol. 2022 03 01; 322(3):F258-F267. PMID: 35037466.
      View in: PubMed
    11. Hopp K, Catenacci VA, Dwivedi N, Kline TL, Wang W, You Z, Nguyen DT, Bing K, Poudyal B, Johnson GC, Jackman MR, Miller M, Steele CN, Serkova NJ, MacLean PS, Nemenoff RA, Gitomer B, Chonchol M, Nowak KL. Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease. iScience. 2022 Jan 21; 25(1):103697. PMID: 35059607.
      View in: PubMed
    12. Nowak KL, Farmer-Bailey H, Wang W, You Z, Steele C, Cadnapaphornchai MA, Klawitter J, Patel N, George D, Jovanovich A, Soranno DE, Gitomer B, Chonchol M. Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults with ADPKD: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2022 02; 17(2):240-250. PMID: 34907021.
      View in: PubMed
    13. Steele C, You Z, Gitomer BY, Brosnahan GM, Abebe KZ, Braun WE, Chapman AB, Harris PC, Perrone RD, Steinman TI, Torres VE, Yu ASL, Chonchol M, Nowak KL. PKD1 Compared With PKD2 Genotype and Cardiac Hospitalizations in the Halt Progression of Polycystic Kidney Disease Studies. Kidney Int Rep. 2022 Jan; 7(1):117-120. PMID: 35005320.
      View in: PubMed
    14. Brosnahan GM, Wang W, Gitomer B, Struemph T, George D, You Z, Nowak KL, Klawitter J, Chonchol MB. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. Am J Kidney Dis. 2022 04; 79(4):518-526. PMID: 34391872.
      View in: PubMed
    15. Nowak KL, Steele C, Gitomer B, Wang W, Ouyang J, Chonchol MB. Overweight and Obesity and Progression of ADPKD. Clin J Am Soc Nephrol. 2021 06; 16(6):908-915. PMID: 34117082.
      View in: PubMed
    16. Nowak KL, Murray K, You Z, Gitomer B, Brosnahan G, Abebe KZ, Braun W, Chapman A, Harris PC, Miskulin D, Perrone R, Torres V, Steinman T, Yu A, Chonchol M. Pain and Obesity in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of the Halt Progression of Polycystic Kidney Disease (HALT-PKD) Studies. Kidney Med. 2021 Jul-Aug; 3(4):536-545.e1. PMID: 34401721.
      View in: PubMed
    17. Baliga MM, Klawitter J, Christians U, Hopp K, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Klawitter J. Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease. Sci Rep. 2021 03 23; 11(1):6629. PMID: 33758231.
      View in: PubMed
    18. Pereira RC, Gitomer BY, Chonchol M, Harris PC, Noche KJ, Salusky IB, Albrecht LV. Characterization of Primary Cilia in Osteoblasts Isolated From Patients With ADPKD and CKD. JBMR Plus. 2021 Apr; 5(4):e10464. PMID: 33869988.
      View in: PubMed
    19. Brosnahan GM, You Z, Wang W, Gitomer BY, Chonchol M. Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials. Curr Hypertens Rev. 2021; 17(3):228-237. PMID: 32807060.
      View in: PubMed
    20. Gitomer B, Pereira R, Salusky IB, Stoneback JW, Isakova T, Cai X, Dalrymple LS, Ofsthun N, You Z, Malluche HH, Maddux F, George D, Torres V, Chapman A, Steinman TI, Wolf M, Chonchol M. Mineral bone disease in autosomal dominant polycystic kidney disease. Kidney Int. 2021 04; 99(4):977-985. PMID: 32926884.
      View in: PubMed
    21. Nowak KL, Farmer-Bailey H, Cadnapaphornchai MA, You Z, George D, Wang W, Jovanovich A, Soranno DE, Gitomer B, Chonchol M. Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease: Design and baseline characteristics of participants. Contemp Clin Trials Commun. 2020 Sep; 19:100635. PMID: 33294724.
      View in: PubMed
    22. Grau L, Gitomer B, McNair B, Wolf M, Harris P, Brosnahan G, Torres V, Steinman T, Yu A, Chapman A, Chonchol M, Nowak KL. Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease. Kidney360. 2020 Jul; 1(7):648-656. PMID: 33305291.
      View in: PubMed
    23. Griffin BR, You Z, Noureddine L, Gitomer B, Perrenoud L, Wang W, Chonchol M, Jalal D. KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results. Am J Nephrol. 2020; 51(6):473-479. PMID: 32541154.
      View in: PubMed
    24. Hopp K, Cornec-Le Gall E, Senum SR, Te Paske IBAW, Raj S, Lavu S, Baheti S, Edwards ME, Madsen CD, Heyer CM, Ong ACM, Bae KT, Fatica R, Steinman TI, Chapman AB, Gitomer B, Perrone RD, Rahbari-Oskoui FF, Torres VE, Harris PC. Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney Int. 2020 02; 97(2):370-382. PMID: 31874800.
      View in: PubMed
    25. Hanudel MR, Salusky IB, Pereira RC, Wang W, You Z, Nowak KL, Brosnahan GM, Torres VE, Chapman AB, Perrone RD, Steinman TI, Bae KT, Gitomer BY, Chonchol MB. Erythropoietin and Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease Patients. Kidney Int Rep. 2019 Dec; 4(12):1742-1748. PMID: 31844811.
      View in: PubMed
    26. Nowak KL, Gitomer B, Farmer-Bailey H, Wang W, Malaczewski M, Klawitter J, You Z, George D, Patel N, Jovanovich A, Chonchol M. Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial. Am J Kidney Dis. 2019 08; 74(2):213-223. PMID: 30803706.
      View in: PubMed
    27. Kleczko EK, Marsh KH, Tyler LC, Furgeson SB, Bullock BL, Altmann CJ, Miyazaki M, Gitomer BY, Harris PC, Weiser-Evans MCM, Chonchol MB, Clambey ET, Nemenoff RA, Hopp K. CD8+ T cells modulate autosomal dominant polycystic kidney disease progression. Kidney Int. 2018 12; 94(6):1127-1140. PMID: 30249452.
      View in: PubMed
    28. Nowak KL, Wang W, Farmer-Bailey H, Gitomer B, Malaczewski M, Klawitter J, Jovanovich A, Chonchol M. Vascular Dysfunction, Oxidative Stress, and Inflammation in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2018 10 08; 13(10):1493-1501. PMID: 30228110.
      View in: PubMed
    29. Nowak KL, Chonchol M, You Z, Gupta M, Gitomer B. Affected parent sex and severity of autosomal dominant polycystic kidney disease: a retrospective cohort study?. Clin Nephrol. 2018 Mar; 89(3):196-204. PMID: 29035198.
      View in: PubMed
    30. Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2018 02; 29(2):571-578. PMID: 29118087.
      View in: PubMed
    31. Chonchol M, Gitomer B, Isakova T, Cai X, Salusky I, Pereira R, Abebe K, Torres V, Steinman TI, Grantham JJ, Chapman AB, Schrier RW, Wolf M. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2017 Sep 07; 12(9):1461-1469. PMID: 28705885.
      View in: PubMed
    32. Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF. A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep. 2017 May; 2(3):451-460. PMID: 29142972.
      View in: PubMed
    33. Nowak KL, Farmer H, Cadnapaphornchai MA, Gitomer B, Chonchol M. Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2017 02 01; 32(2):342-347. PMID: 28186577.
      View in: PubMed
    34. Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF. Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in?Patients With Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep. 2017 May; 2(3):442-450. PMID: 29142971.
      View in: PubMed
    35. Nowak KL, Cadnapaphornchai MA, Chonchol MB, Schrier RW, Gitomer B. Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol. 2016; 44(3):171-8. PMID: 27548646.
      View in: PubMed
    36. Klawitter J, McFann K, Pennington AT, Wang W, Klawitter J, Christians U, Schrier RW, Gitomer B, Cadnapaphornchai MA. Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2015 Sep 04; 10(9):1534-41. PMID: 26224879.
      View in: PubMed
    37. Perrone RD, Neville J, Chapman AB, Gitomer BY, Miskulin DC, Torres VE, Czerwiec FS, Dennis E, Kisler B, Kopko S, Krasa HB, LeRoy E, Castedo J, Schrier RW, Broadbent S. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis. 2015 Oct; 66(4):583-90. PMID: 26088508.
      View in: PubMed
    38. Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, Rossetti S. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol. 2014 Nov; 25(11):2399-418. PMID: 24925719.
      View in: PubMed
    39. Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014 May; 9(5):889-96. PMID: 24721893.
      View in: PubMed
    40. Klawitter J, Klawitter J, McFann K, Pennington AT, Abebe KZ, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Gitomer B, Christians U, Schrier RW. Bioactive lipid mediators in polycystic kidney disease. J Lipid Res. 2014 06; 55(6):1139-49. PMID: 24343898.
      View in: PubMed
    41. Klawitter J, Zafar I, Klawitter J, Pennington AT, Klepacki J, Gitomer BY, Schrier RW, Christians U, Edelstein CL. Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease. BMC Nephrol. 2013 Jul 31; 14:165. PMID: 23902712.
      View in: PubMed
    42. Liu M, Shi S, Senthilnathan S, Yu J, Wu E, Bergmann C, Zerres K, Bogdanova N, Coto E, Deltas C, Pierides A, Demetriou K, Devuyst O, Gitomer B, Laakso M, Lumiaho A, Lamnissou K, Magistroni R, Parfrey P, Breuning M, Peters DJ, Torra R, Winearls CG, Torres VE, Harris PC, Paterson AD, Pei Y. Genetic variation of DKK3 may modify renal disease severity in ADPKD. J Am Soc Nephrol. 2010 Sep; 21(9):1510-20. PMID: 20616171.
      View in: PubMed
    43. Amura CR, Brodsky KS, Gitomer B, McFann K, Lazennec G, Nichols MT, Jani A, Schrier RW, Doctor RB. CXCR2 agonists in ADPKD liver cyst fluids promote cell proliferation. Am J Physiol Cell Physiol. 2008 Mar; 294(3):C786-96. PMID: 18199703.
      View in: PubMed
    Gitomer's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (157) concept(s)
    _
    Co-Authors Expand Description
    See all (20) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)